ALNY – alnylam pharmaceuticals, inc. (US:NASDAQ)
Stock Stats
News
2/1
12:32 am
alny
Low
Alnylam Pharmaceuticals (ALNY) Valuation Check After Recent Share Price Weakness [Yahoo! Finance]
1/31
07:03 pm
alny
Low
Analyst Views Diverge as Alnylam Pharmaceuticals, Inc. (ALNY) Targets $5.1B Revenue and Long-Term Growth [Yahoo! Finance]
1/30
12:26 pm
alny
Low
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Morgan Stanley from $495.00 to $408.00. They now have an "equal weight" rating on the stock.
1/30
08:03 am
alny
Low
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at HC Wainwright from $570.00 to $510.00. They now have a "buy" rating on the stock.
1/30
08:03 am
alny
Low
Alnylam Pharmaceuticals (NASDAQ:ALNY) had its price target lowered by analysts at Bank of America Corporation from $529.00 to $462.00. They now have a "buy" rating on the stock.
10/30/2025
08:00 am
alny
-2.3%
BEAT
7/31/2025
08:00 am
alny
12.4%
BEAT
5/1/2025
08:00 am
alny
-3.7%
BEAT
2/13/2025
08:00 am
alny
-1.5%
BEAT
1/30
11:49 am
Maintains
Equal-Weight
Equal-Weight
Morgan Stanley
Low
-0.9%
1/30
11:49 am
Maintains
Equal-Weight
Equal-Weight
Morgan Stanley
Low
-0.9%
1/28
08:10 am
Initiates
Overweight
Barclays
Low
-1.5%
1/28
08:10 am
Initiates
Overweight
Barclays
Low
-1.5%
1/28
08:03 am
Initiates
Overweight
Barclays PLC
Low
-1.5%
1/14
04:23 pm
alny
Low
Form 4 ALNYLAM PHARMACEUTICALS, For: Jan 11 Filed by: Garg Pushkal
1/14
04:23 pm
alny
Low
Form 4 ALNYLAM PHARMACEUTICALS, For: Jan 11 Filed by: Poulton Jeffrey V.
1/14
04:23 pm
alny
Low
Form 4 ALNYLAM PHARMACEUTICALS, For: Jan 11 Filed by: Greenstreet Yvonne
1/14
04:22 pm
alny
Low
Form 4 ALNYLAM PHARMACEUTICALS, For: Jan 11 Filed by: Fitzgerald Kevin Joseph
1/14
04:22 pm
alny
Low
Form 4 ALNYLAM PHARMACEUTICALS, For: Jan 11 Filed by: Tanguler Tolga
Show more
Top News Gainers
8/6 Form 10-Q ALNYLAM PHARMACEUTICALS, For: Jun 30 11.4%
11/19 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) is now covered by analysts at Oppenheimer Holdings Inc.. They set an "outperform" rating and a $128.00 price target on the stock. 10.5%
3/12 Why Alnylam Pharmaceuticals, Intuitive Surgical, and ResMed Stocks Sank Today [The Motley Fool] 9.1%
8/6 Form 8-K ALNYLAM PHARMACEUTICALS, For: Aug 06 6.3%
4/6 Alnylam and Dicerna Form RNAi Therapeutics Collaboration on Alpha-1 Antitrypsin Deficiency-Associated Liver Disease and Complete Cross-License Agreement for Primary Hyperoxaluria Programs 6.0%
11/18 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $120.00 price target on the stock. 5.6%
11/22 Form 4 ALNYLAM PHARMACEUTICALS, For: Nov 20 Filed by: Greenstreet Yvonne 5.2%
10/31 Alnylam Pharmaceuticals, Inc. 2019 Q3 - Results - Earnings Call Presentation [Seeking Alpha] 4.9%
11/26 Alnylam to Webcast Presentations at Upcoming December Investor Conferences 4.9%
2/9 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its "buy" rating re-affirmed by analysts at Cowen Inc. They now have a $154.00 price target on the stock. 4.8%
Top News Decliners
12/17 Alnylam gene-silencing therapy to treat kidney disorder succeeds in late-stage study [Reuters (UK)] -11.7%
3/10 Alnylam Pharmaceuticals (ALNY) Presents At Barclays Global Healthcare Conference - Slideshow [Seeking Alpha] -6.9%
2/21 Form 4 ALNYLAM PHARMACEUTICALS, For: Feb 20 Filed by: MARAGANORE JOHN -6.7%
11/22 Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY) had its price target raised by analysts at Morgan Stanley from $124.00 to $141.00. They now have an "overweight" rating on the stock. -4.7%
4/13 Alnylam's stock surges after Blackstone confirms $2 billion investment [MarketWatch] -4.4%
9/26 Alnylam to Webcast Presentation at 2019 Cantor Global Healthcare Conference -4.3%
3/16 Alnylam shows wild action on a wild day [Seeking Alpha] -4.2%
5/3 Form SC 13G/A ALNYLAM PHARMACEUTICALS, Filed by: Sanofi -4.2%
9/6 Alnylam to Host Sixth Annual “RNAi Roundtable” Webcast Series -4.0%
1/10 Alnylam Initiates Rolling Submission of New Drug Application (NDA) to U.S. Food and Drug Administration (FDA) for Lumasiran for the Treatment of Primary Hyperoxaluria Type 1 (PH1) -3.9%
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.
Click Here To Register For The Live Online Workshop
In short, News Quantified specializes in matching financial news with market data. We've analyzed 10s of millions of news events and know exactly which ones have an outsized impact on stock prices. So every single time a news item is released we know exactly what the average effect will be on a particular stock.

Latest Posts

Trading the Google Earnings Announcement: A Strategic Preview
Earnings Week Wrap-up and Takeaways
Earnings Season: Q3 Review, Q4 Kickoff – Morgan Stanley, Bank of America, Goldman Sachs, Netflix
Guerrilla Learning Opportunity: Wealth365 Conference Featuring News Quantified Founder and Much More
The Smart Way to Ten Minutes Per Day

Information

Support

Contact us

20715 N Pima Rd #F108
Scottsdale, AZ 85255
Email: info@newsquantified.com
Copyright Ⓒ News Quanitifed LLC. 1.1.3